Skip to content 
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, Sequel, Sequel II, and Sequel IIe instruments which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. It serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California. more
| Time Frame | PACB | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | -11.41% | 0.72% | -1.31% |
| 1-Month Return | -30.93% | 1.27% | 0.78% |
| 3-Month Return | -1.21% | 3.13% | 3.46% |
| 6-Month Return | 22.56% | 15.81% | 6.19% |
| 1-Year Return | -12.83% | 8.89% | 11.68% |
| 3-Year Return | -82.17% | 20.79% | 71.21% |
| 5-Year Return | -96.19% | 35.89% | 74.81% |
| 10-Year Return | -80.29% | 138.44% | 256.59% |
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 130.51M | 128.30M | 200.52M | 154.01M | 160.00M | [{"date":"2021-12-31","value":65.09,"profit":true},{"date":"2022-12-31","value":63.99,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":76.81,"profit":true},{"date":"2025-12-31","value":79.79,"profit":true}] |
| Cost of Revenue | 71.65M | 79.27M | 147.74M | 116.73M | 109.33M | [{"date":"2021-12-31","value":48.5,"profit":true},{"date":"2022-12-31","value":53.65,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":79.01,"profit":true},{"date":"2025-12-31","value":74,"profit":true}] |
| Gross Profit | 58.86M | 49.03M | 52.78M | 37.28M | 50.67M | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":83.31,"profit":true},{"date":"2023-12-31","value":89.67,"profit":true},{"date":"2024-12-31","value":63.34,"profit":true},{"date":"2025-12-31","value":86.09,"profit":true}] |
| Gross Margin | 45.10% | 38.22% | 26.32% | 24.21% | 31.67% | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":84.74,"profit":true},{"date":"2023-12-31","value":58.36,"profit":true},{"date":"2024-12-31","value":53.68,"profit":true},{"date":"2025-12-31","value":70.22,"profit":true}] |
| Operating Expenses | 269.30M | 356.23M | 387.25M | 511.60M | 608.24M | [{"date":"2021-12-31","value":44.27,"profit":true},{"date":"2022-12-31","value":58.57,"profit":true},{"date":"2023-12-31","value":63.67,"profit":true},{"date":"2024-12-31","value":84.11,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Operating Income | (210.44M) | (307.20M) | (334.47M) | (474.31M) | (557.56M) | [{"date":"2021-12-31","value":-21043500000,"profit":false},{"date":"2022-12-31","value":-30719600000,"profit":false},{"date":"2023-12-31","value":-33446700000,"profit":false},{"date":"2024-12-31","value":-47431300000,"profit":false},{"date":"2025-12-31","value":-55756100000,"profit":false}] |
| Total Non-Operating Income/Expense | (76.97M) | (21.74M) | 1.89M | 151.37M | - | [{"date":"2021-12-31","value":-50.85,"profit":false},{"date":"2022-12-31","value":-14.36,"profit":false},{"date":"2023-12-31","value":1.25,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Pre-Tax Income | (274.87M) | (314.25M) | (318.16M) | (309.54M) | (546.06M) | [{"date":"2021-12-31","value":-27487200000,"profit":false},{"date":"2022-12-31","value":-31424800000,"profit":false},{"date":"2023-12-31","value":-31815900000,"profit":false},{"date":"2024-12-31","value":-30953500000,"profit":false},{"date":"2025-12-31","value":-54605800000,"profit":false}] |
| Income Taxes | (93.65M) | (17.32M) | (11.42M) | 316.00K | 318.00K | [{"date":"2021-12-31","value":-29449.37,"profit":false},{"date":"2022-12-31","value":-5445.91,"profit":false},{"date":"2023-12-31","value":-3592.45,"profit":false},{"date":"2024-12-31","value":99.37,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Income After Taxes | (181.22M) | (296.93M) | (306.74M) | (309.85M) | - | [{"date":"2021-12-31","value":-18122300000,"profit":false},{"date":"2022-12-31","value":-29693000000,"profit":false},{"date":"2023-12-31","value":-30673500000,"profit":false},{"date":"2024-12-31","value":-30985100000,"profit":false},{"date":"2025-12-31","value":"-","profit":true}] |
| Income From Continuous Operations | (181.22M) | (314.25M) | (309.10M) | (309.85M) | - | [{"date":"2021-12-31","value":-18122300000,"profit":false},{"date":"2022-12-31","value":-31424800000,"profit":false},{"date":"2023-12-31","value":-30910100000,"profit":false},{"date":"2024-12-31","value":-30985100000,"profit":false},{"date":"2025-12-31","value":"-","profit":true}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Net Income | (181.22M) | (314.25M) | (306.74M) | (309.85M) | (546.38M) | [{"date":"2021-12-31","value":-18122300000,"profit":false},{"date":"2022-12-31","value":-31424800000,"profit":false},{"date":"2023-12-31","value":-30673500000,"profit":false},{"date":"2024-12-31","value":-30985100000,"profit":false},{"date":"2025-12-31","value":-54637600000,"profit":false}] |
| EPS (Diluted) | (1.20) | (1.40) | (1.21) | (1.30) | (0.52) | [{"date":"2021-12-31","value":-120,"profit":false},{"date":"2022-12-31","value":-140,"profit":false},{"date":"2023-12-31","value":-121,"profit":false},{"date":"2024-12-31","value":-130,"profit":false},{"date":"2025-12-31","value":-52,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| PACB | |
|---|---|
| Cash Ratio | 5.14 |
| Current Ratio | 6.89 |
| Quick Ratio | 5.99 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| PACB | |
|---|---|
| ROA (LTM) | -34.09% |
| ROE (LTM) | -213.45% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| PACB | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.99 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.01 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| PACB | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 2.98 |
| P/B | 96.43 |
| EV/R | 5.87 |
| EV/Ebitda | NM |
| PEG | NM |
Pacific Biosciences of California (PACB) share price today is $1.63
Yes, Indians can buy shares of Pacific Biosciences of California (PACB) on Vested. To buy
Yes, you can purchase fractional shares of Pacific Biosciences of California (PACB) via the Vested app. You can start investing in Pacific Biosciences of California (PACB) with a minimum investment of $1.
You can invest in shares of Pacific Biosciences of California (PACB) via Vested in three simple steps:
The 52-week high price of Pacific Biosciences of California (PACB) is $2.73. The 52-week low price of Pacific Biosciences of California (PACB) is $0.85.
The price-to-earnings (P/E) ratio of Pacific Biosciences of California (PACB) is
The price-to-book (P/B) ratio of Pacific Biosciences of California (PACB) is 96.43
The dividend yield of Pacific Biosciences of California (PACB) is 0.00%
The market capitalization of Pacific Biosciences of California (PACB) is $477.01M
The stock symbol (or ticker) of Pacific Biosciences of California is PACB
Consider the share price of Pacific Biosciences of California as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Pacific Biosciences of California has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Pacific Biosciences of California shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Pacific Biosciences of California stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Pacific Biosciences of California and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Pacific Biosciences of California stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
